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Abstract Purpose:Alveolar soft part sarcoma (ASPS) is a rare, chemoresistant soft tissue sarcoma. ASPS
harbors the t(17-X) (p11.2;q25) translocation, resulting in the ASPACR1-TFE3 fusion protein,
causing METautophosphorylation and activation of downstream signaling. The tumor vascular
pattern prompted us to use sunitinib malate (SM), a tyrosine kinase inhibitor with antiangiogenic
properties.
Experimental Design: Since July 2007, five patients with progressive metastatic ASPS have
been treated with continuous SM 37.5 mg/d on a named basis. Four patients are evaluable for
response. In four cases, cryopreserved material was available. Upstream and downstream
targets of receptor tyrosine kinase (RTK) pathways, as well as mechanisms of activation, were
investigated by biochemical profiles, including human phospho-receptor RTK antibody arrays
and immunoprecipitation/Western blotting, molecular analyses, immunohistochemistry, and fluo-
rescence in situ hybridization analyses.
Results: After 3 months, two patients had RECIST (response evaluation criteria in solid tumor)
partial response, as well as positron emission tomography response and subjective improvement.
One had a RECIST stable disease. One progressed and stopped treatment. One patient is still
responding after 12 months. The upstream analysis showed activation of all the platelet-derived
growth factor receptor (PDGFR) family members, as well as epidermal growth factor receptor,
MET families, and RET. Vascular endothelial growth factor receptors (VEGFR1and VEGFR2)
were activated only in one case. The downstream target analysis showed strong activation of
phosphatidylinositol 3-kinase/AKT, extracellular signal-regulated kinase 1/2, and mTOR and its
targets (S6K and S6).The absence of any upstreammTOReffector deregulation and thepresence
of RTK cognate ligands support an autocrine-paracrine activation loop mechanism.
Conclusion: SMmay have antitumor activity in ASPS, possibly through a mechanism involving
PDGFRand RET.The role ofMET, epidermal growth factor receptor, andmTOR, aswell as PDGFR
inhibition, needs to be further explored.
Alveolar soft part sarcoma (ASPS) is a very rare sarcoma
(incidence 0.5/100,000/year) of uncertain histogenesis, main-
ly affecting deep soft tissues of the extremities of young
patients (15-35 years; ref. 1). ASPS has a high metastatic
potential to the lungs, bone, liver, soft tissue, and brain. Most
patients who metastasize cannot be cured and have a
definitely poor prognosis in spite of a prolonged natural
history. Chemotherapy has long been known to be inactive in
ASPS (1–3). Reports of tumor responses to IFN have been
only anecdotal (4–6). Histologically, ASPS consists of
epithelioid, poorly cohesive tumoral cells arranged in nests,
accompanied by prominent capillary vascularity. ASPS carries
a translocation t(X;17)(p11.2;q25) resulting in the ASPACR1-
TFE3 fusion gene (previously designated ASPL-TFE3; ref. 7).
Two recent preclinical investigations (8, 9) pointed out the
role of unregulated TFE3 overexpression in the context of
ASPSCI-TFE3 fusion transcript, which leads to activation of
MET and its downstream signaling that may represent
potential targets of receptor tyrosine kinase (RTK) inhibitors.
In the lack of any therapeutic alternative in a group of
progressive advanced ASPS resistant to IFN, the peculiar
vascular pattern of this disease prompted us to use sunitinib
malate (SM; SU11248, Sutent), a known RTK inhibitor with
antiangiogenic properties approved for treatment of GIST and
renal cancer (10–14). SM is an RTK inhibitor with direct
antitumor and antiangiogenic activity targeting platelet-derived
growth factor receptor (PDGFR), KIT, FTL3, M-CSF, all
Cancer Therapy: Clinical
Authors’ Affiliations: Departments of 1Cancer Medicine, 2Pathology and
Molecular Biology, 3Nuclear Medicine, 4Radiology, and 5Surgery, Fondazione
IRCCS Istituto NazionaleTumori, Milan, Italy
Received 8/5/08; revised10/10/08; accepted10/17/08.
Grant support: Associazione Italiana per la Ricerca sul Cancro grant (S. Pilotti).
The costs of publication of this article were defrayed in part by the payment of page
charges.This article must therefore be hereby marked advertisement in accordance
with18 U.S.C. Section1734 solely to indicate this fact.
Note: P.G. Casali and S. Pilotti contributed equally to this work.
Presented at the 44th American Society of Clinical Oncology Annual Meeting,
2008, Chicago.
Role of the funding source: Pfizer srl provided the drug on a case-by-case basis and
was informedof the results.The corresponding authorhad the final responsibility for
the decision to submit the paper for publication and wrote the manuscript in
cooperation with all the other authors. The company played no role in writing or
revising themanuscript.
Requests for reprints: Silvia Stacchiotti, Department of Cancer Medicine,
Fondazione IRCCS Istituto NazionaleTumori, viaVenezian1, 20133Milan, Italy. Phone:
390223902803; Fax: 390223902804; E-mail: silvia.stacchiotti@istitutotumori.mi.it.
F2009 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-08-2050
www.aacrjournals.orgClin Cancer Res 2009;15(3) February1, 2009 1096
Research. 
on May 15, 2019. © 2009 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
belonging to the PDGFR family, vascular endothelial growth
factor receptors (VEGFR) and RET (15–17). We have also
studied the biochemical-molecular-cytogenetic profile of four
primary ASPSs to gain deeper insights into the RTK expression/
activation status, the upstream and downstream signaling, and
their activation mechanisms.
Materials andMethods
Biochemical, molecular, and cytogenetic analyses were done on four
ASPS primary tumors operated at our institution and whose cryopre-
served material was available. In all cases, diagnosis were confirmed by
positive immunostaining for TFE3 and by interphase fluorescence
in situ hybridization (FISH) using a probe for 17q25.3 mapping
telomeric to ASPL in combination with a centromere 17–specific probe
(Table 1A and B).
Patients treated in this series had to have an unresectable progressive
ASPS during the previous 3 mo according to RECIST (response
evaluation criteria in solid tumor; ref. 18). A performance status
(Eastern Cooperative Oncology Group) of V3 and an adequate bone
marrow and organ function were also requested. Patient’s written
informed consent to a nonconventional medical treatment, selected in
the lack of alternative therapies known to be effective in the disease, was
required, and all patients were aware that there was no previously
reported proof of antitumor activity and efficacy of SM in ASPS. The
ethical committee approved the use of the drug in all cases.
Treatment. Patients were treated with continuous 37.5 mg of SM
once daily, within a compassionate use program. Treatment was
continued as long as there was no disease progression. Treatment was
withheld for hematologic grade of z3 adverse events and for
nonhematologic grade of z2 adverse event (defined according to the
National Cancer Institute Common Toxicity Criteria, version 3.0) and
restarted after recovery to grade of <2 in case of hematologic or grade of
<1 in case of nonhematologic.
Evaluation. At baseline, all patients were evaluated with a complete
history and physical examination, a complete blood count and serum
chemistry (comprehensive of ANC, platelet, haemoglobin, creatinine,
bilirubin, SGOT, SGPT, ALP, LDH, cholesterol, triglycerides, FT3, FT4,
TSH, CPK) and full cardiologic assessment. Adverse events, serum
chemical analyses, and blood count were monitored after 2 wk from
treatment start and then monthly, but in case of problems. Required
imaging studies before treatment included a whole body computed
tomography scan and a computed tomography scan and magnetic
resonance imaging of the sites of disease; baseline positron emission
tomography (PET) scan was done in all cases. Scanning was repeated
after 6 wk from treatment start then every 3 mo.
Efficacy assessment. Response to treatment was assessed with the
use of RECIST criteria and PET response, according to the currently
available European Organization for Research and Treatment of Cancer
1999 tumor response criteria (18, 19).
Analyses of frozen surgical material
Phosphorylation of RTK array. Expression of phosphorylated growth
factor RTKs was detected using the Proteome Profiler Array kit (R&D
Systems). The procedures were done according to the manufacturer’s
protocol using 2 mg protein lysate per array.
Total protein extraction, immunoprecipitation, and Western blot-
ting. Total proteins were extracted and immunoprecipitated with
specific antibodies, as previously reported (20). Experimental condi-
tion for PDGFRA, PDGFRB, and epidermal growth factor receptor
(EGFR) immunoprecipitation and subsequent Western blotting were
already reported (20). Rabbit polyclonal anti-MET (20 AL, Santa Cruz
Biotechnology) and rabbit polyclonal anti-RET (5 AL, Santa Cruz
Biotechnology) were used for MET and RET immunoprecipitation. For
Western blotting, the same MET antibody and the anti–P-RET (Santa
Cruz Biotechnology) were used. The downstream signaling analysis
was done by direct Western blotting, loading 20 Ag of total protein
per lane, using the following antibodies and the dilutions listed in
Table 1C.
Molecular analysis. Mutational analysis of EGFR, PDGFRA, and
PDGFRB was done, as previously described (20), whereas RET
mutations were analyzed according to Borrello et al. (21). Phosphati-
dylinositol 3-kinase (PI3K) hot spot mutations were studied, as
reported in Moroni et al. (22), whereas RAS (K/N and H) and BRAF
were investigated according to Frattini et al. (23). PTEN was analyzed
using the primers and experimental conditions listed in Table 1D.
Total RNA was extracted and reverse-transcribed, as previously
described (24). Expression of PDGFRB and PDGFRA ligands was done
according to Tamborini et al. (20). MET ligand (HGF) and RET ligands
(GDNF and NTN) were amplified using the specific primers listed in
Table 1D. EGFR ligands (EGF and TGFA) were analyzed by real-time
PCR using the specific probes listed in Table 1D.
Analysis of formalin-fixed paraffin-embedded material
Immunohistochemistry. Immunohistochemistry was done on 2 Am
formalin-fixed and paraffin-embedded sections using specific anti-
bodies directed against TFE3, EGFR, PDGFRB, PDGFRA, MET, RET, and
KIT. The details of the antibodies are shown in Table 1A.
FISH analysis. FISH analysis was done on paraffin-embedded
sections, in which representative areas were selected under microscopic
control, as previously described (25), using the probes described in
Table 1B.
The analysis for PDGFRA and PDGFRB has already been reported
(20). The corresponding gene status was evaluated, as previously
described (disomic, low polysomy, high polysomy; refs. 26, 27).
Results
As of June 2008 and from July 2007, five patients (patients
A-E; Table 2) with advanced ASPS resistant to IFN have been
Translational Relevance
We investigated the upstream and downstream tyrosine
kinase ^ related pathways in alveolar soft part sarcoma
throughphospho-receptor tyrosine kinase antibody arrays,
immunoprecipitation/Western blotting, mutational ana-
lyses, immunohistochemistry, and fluorescence in situ
hybridization. In all cases, the upstream analysis showed
activation of the platelet-derived growth factor receptor
family, as well as epidermal growth factor receptor,
MET families, and RET.Vascular endothelial growth factor
receptors (VEGFR1 and VEGFR2) were activated only
in one case. The downstream target analysis showed a
strong activation of phosphatidylinositol 3-kinase/AKT,
extracellular signal-regulated kinase 1/2, and mTOR and its
targets without any upstream mTOR effector deregulation.
No evidence of mutations and gain or loss of genes were
found, whereas a consistent presence of cognate ligands
was promptly detected. These findings give a rationale to
the use of sunitinib malate, because sunitinib malate is a
receptor tyrosine kinase inhibitor with direct antitumor and
antiangiogenic activity by targeting the platelet-derived
growth factor receptor family and vascular endothelial
growth factor receptors, as well as RETreceptor.
Sunitinib in Advanced ASPS
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Table 1. Antibodies and their working dilutions are listed for immunochemistry (A) and Western blotting (C)
analyses and all the primers and amplification conditions, including real-time PCR, are reported (D) for
molecular investigations and for all the probe FISH employed in the study (B)
C
Antibody Clone Company Dilution Positive control
P Akt 4058S Ser473 Cell Signaling 1:1000 A431 cell line
Akt 9272 Cell Signaling 1:1000 A431 cell line
P MAPK 4376S Thr 202/Tyr204 Cell Signaling 1:1000 A431 cell line
MAPK 9102 Cell Signaling 1:1000 A431 cell line
P m-TOR 2971S Ser2448 Cell Signaling 1:1000 A431 cell line
m-TOR 2972 Cell Signaling 1:1000 A431 cell line
P p70S6K 9234S Thr389 Cell Signaling 1:1000 A431 cell line
p70S6K 9202 Cell Signaling 1:1000 A431 cell line
P S6 2215L Ser 240/244 Cell Signaling 1:2000 A431 cell line
S6 2217 Cell Signaling 1:1000 A431 cell line
PTEN 9559 Cell Signaling 1:2000 A431 cell line
Actin A2066 Sigma 1:5000 A431 cell line
D
Gene Primers PCR conditions
PTEN exon 5 fw 5¶-TGCAACATTTCTAAAGTTACCTACT-3¶ 96jC 8 min; 96jC 30 s, 55jC 30 s, 72jC 1 min:
exon 5 rev 5¶-GAGGAAAGGAAAAACATCAAAAA-3¶ 40 cycles; 72jC 7 min
exon 6 fw 5¶-TTTTTCAATTTGGCTTCTCTTTTT-3¶
exon 6 rev 5¶-TGTTCCAATACATGGAAGGATG-3¶
exon 7 fw 5¶-CAGTTAAAGGCATTTCCTGTG-3¶
exon 7 rev 5¶-TTTTGGATATTTCTCCCAATGAA-3¶
exon 8 fw 5¶-TGTCATTTCATTTCTTTTTCTTTTC-3¶
exon 8 rev 5¶-AAGTCAACAACCCCCACAAA-3¶
exon 9 fw 5¶-TCATGGTGTTTTATCCCTCTTG-3¶
exon 9 rev 5¶-TGAGTCATATTTGTGGGTTTTCA-3¶
HGF fw 5¶-GGGAAATGAGAAATGCAGCCAG-3¶ 96jC 8 min; 94jC 1 min, 58jC 1 min, 72jC 1 min: 5 cycles;
rev 5¶-AGTTGTATTGGTGGGTGCTTC-3¶ 94jC 30 s, 59jC 30 s, 72jC 1 min: 35 cycles; 72jC 5 min
GDNF fw 5¶-TGAAGTTATGGGATGTCGTGG-3¶ 96jC 8 s; 95jC 1 min, 62jC 30 s, 72jC 1 min:
rev 5¶-TACTTTGTCACTCACCAGCCTT-3¶ 40 cycles; 72jC 5 min
NTN ex fw 5¶-GCTGTCCATCTGGATGTGTC-3¶ 95jC 5 min; 95jC 15 s, 62jC 15 s, 72jC 1 min:
ex rev 5¶-AAGGACACCTCGTCCTCGTAG-3¶ 40 cycles; 72jC 5 min
int fw 5¶-GAGAGGGCCTGCTTCTCGA-3¶ 95jC 5 min; 95jC 15 s, 58jC 15 s, 72jC 1 min:
int rev 5¶-GAACAGCACCGTCTCGTCGGA-3¶ 40 cycles; 72jC 5 min
Ligands Probes Real-time PCR conditions
EGF Hs00153481_M1 Applied Biosystem 50jC 2 min; 95jC 10; 95jC
TGFA Hs00608187_M1 15 s, 60jC 1 min: 40 cycles
A
Antibody Clone Company Dilution Antigen retrieval Positive control
EGFR K1492 Dako The procedures were done according to the manufacturer’s protocol
PDGFRB sc-339 Santa Cruz Biotec 1:100 6 min at 95jC 5 mmol/L citrate buffer, pH 7 Human breast carcinoma
PDGFRA sc-338 Santa Cruz Biotec 1:200 6 min at 95jC 5 mmol/L citrate buffer, pH 6 Exon 18 PDGFRA
mutated GIST
MET sc-10 Santa Cruz Biotec, CA, USA 1:50 15 min at 95jC 1 mmol/L EDTA buffer, pH 8 Human breast carcinoma
RET 3F8 Vector Laboratories 1:20 15 min at 95jC 1 mmol/L EDTA buffer, pH 8 Small intestine
CD117 A4502 Dako 1:50 6 min at 95jC 5 mmol/L citrate buffer, pH 6 Exon 11 c-kit
mutated GIST
TFE3 SC-5958 Santa Cruz Biotec 1:250 6 min at 95jC 1 mmol/L EDTA buffer, pH 8 Pediatric renal
adenocarcinoma
B
Gene Probe Company
PTEN LSI PTEN/CEP10 dual-color probe Vysis
EGFR LSI EGFR/CEP7 dual-color probe Vysis
MET LSI D7S552 (7q31) Spectrum Orange/7Spectrum Green Probe Vysis
RET BAC clone RP11-231C18 labeled with Spectrum Green dUTP
coupled with CEP10 Spectrum Orange SO
Dr. M. Rocchi (Resources for
Molecular Cytogenetic,
University of Bari)
ASPL BAC clone RP11-525L23 labeled with Spectrum Orange
dUTP coupled with CEP17 Spectrum Green SO
Invitrogen
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treated with continuous SM at 37.5 mg/d. Among them, four
are still on therapy, whereas one has stopped treatment after 3
months for progressive disease. Four are evaluable for response,
whereas one has just started his treatment. Pretreatment frozen
surgical specimens from primary tumor were available for two
of four patients (patients A and B). Two additional specimens
again from primary tumor were assessed, from patients F and G
not treated in this series.
Patients
Patient characteristics are listed in Table 2 [mean age/
range, 35 years/22-58 years; female/male, 1/6; site: five lower
limbs and two upper limbs; locoregional/metastatic: 0/7,
with involvement of the lung (7), liver (4), soft tissue (3),
bone (2), brain (2)]. The WHO performance status of three
of them was z2. All patients had been heavily pretreated
with one or more surgical procedures (7), radiotherapy (5),
and medical therapy (7). Three of them were symptomatic
for pain and functional impairment requiring constant
treatment. All patients had progressed within 3 mo before
starting treatment.
The mean duration of treatment was 5 mo (range, 1-12
months). All patients received SM of 37.5 mg/d, according to a
continuous dosing regimen. In all patients stopping their
treatment for toxicity, the drug was then restarted at the same
dose level.
Overall, SM was well tolerated. The major nonhematologic
toxicities include fatigue (one case, G2), hypothyroidism (one
case, G2), and nausea and vomit (G2). The most common
hematologic toxicities were neutropenia (three patients, no
G3-4), chronic anemia (one patient, no G3-4), and thrombo-
cytopenia (1 patient, no G3-4). No treatment interruptions for
G3 toxicity were required. No dose reductions were required
due to adverse event.
Response
Clinical findings. As shown in Table 3, four patients (A-D)
are evaluable for response. According to RECIST, after 1 month
of treatment, two patients (A and B) had a partial response, one
patient (D) was stable, and one patient (C) was slightly
progressive. After 3 months, patients A and B were still
responding, patient D was stable, and patient C had a
progressive disease and stopped his treatment. Patient A is still
responding after 12 months of treatment, with a slow
continuous decrease in size and PET uptake. Patient B
progressed after 9 months, although without a RECIST
progressive disease, so that he is still on therapy. PET confirmed
response in patient B. Computed tomography scan responses
are shown in Figs. 1 and 2.
Patients A and B reported improvement in symptoms.
Interestingly, patient A had an increase of subcutaneus lesions
during treatment interruption, and a decrease once on therapy
again.
Pathology/biology
1. Upstream targets. Because SM blocks the activity of
multiple receptors, we evaluated the expression profile of different
RTKs in primary tumor of four ASPS patients. Two of these
patients received SM (patients A and B). This analysis showed a
heterogeneous activation profile. As shown in Fig. 3A, we
observed a high level of activation of members belonging to the
PDGFR family (PDGFRB, Flt3, M-CSFR) and EGFR family (EGFR,
Her4), followed by HGFR family (HGFR and MSPR) and VEGFR
family (VEGFR1 and VEGFR2). The activation of Axl/Dtk, FGFR3,
and IR seems to be less relevant, because drugs against these
receptors are lacking at present.
Confirmatory immunohistochemistry and biochemical analyses
Immunohistochemistry. To confirm the data derived from
the phospho RTK antibody arrays, we did immunostaining
for EGFR, PDGFRB and MET, extending the analysis to the
remaining members of PDGFR family (PDGFRA and CD117)
and RET on formalin-fixed paraffin-embedded representative
selected sections.
EGFR resulted null in all but one case, which scored as
intermediate (case F; data not shown). PDGFRB was expressed
in all cases, but one result was not evaluable (case B, data not
shown). MET was immunoreactive in all the four cases, as
shown in Fig. 3B (left).
PDGFRA (data not shown) and RET (Fig. 3B, right) were
expressed in all the four cases, whereas CD 117 resulted null
(data not shown).
RET was investigated because of MET overexpression, which
might be related to upstream signals generated by RAS or RET
activation (and by possible other oncogenes; ref. 28).
The discrepancy between phospho RTK antibody arrays and
Western blotting is possibly due to the different efficacy of the
applied antibodies.
Biochemical analysis: immunoprecipitation and Western blotting.
Expression and phosphorylation status of EGFR, PDGFRA,
PDGFRB, MET, and RET receptors were assessed by immuno-
precipitation/Western blotting on the residual protein extracts
used for phospho RTK antibody arrays.
EGFR and PDGFRB were expressed and activated in all the
four samples. PDGFRA was also expressed but with a lower
phosphorylation level (data not shown).
MET and RET were expressed and phosphorylated in all
the four samples with a weaker activation level in samples G
and B for MET (Fig. 3B, left) and sample F for RET (Fig. 3B,
right).
Taken together, with the exception of EGFR (finding otherwise
not unexpected; ref. 25), there was a good correlation between
immunohistochemistry and biochemical analysis and between
this latter and phospho RTK antibody array results.
2. Downstream targets
Biochemical analyses (immunoprecipitation/Western blotting). As
PI3K/AKT cascade, coimmunoprecipitation experiments with
PDGFRA, MET, RET, EGFR, and PDGFRB showed in all the
samples the presence of p85, the regulatory subunit of PI3K,
which is consistent with an upstream RTK-mediated activation
of p85 (Fig. 3C, top left , coimmunoprecipitation of p85 with
PDGFRB and EGFR).
Regarding RAS/extracellular signal-regulated kinase 1/2
(ERK1/2) pathway, ERK1/2 showed high levels of expression
and activation (Fig. 3C, intermediate and bottom left).
Furthermore, in keeping with the literature pointing out that
not only PI3K/AKT but also RAS/ERK1/2 triggers mTOR (29),
we observed mTOR expression and activation in all the four
samples (Fig. 3C, top right), and the same was true for its
downstream targets, the p70S6K and the ribosomal protein S6
(Fig. 3C, intermediate and bottom right).
Overall, both thePI3K/AKTandERK1/2pathwayswere activated.
Mutational analysis. p110, the catalytic subunit of PI3K, PTEN,
RAS, and BRAF were sequenced, and no mutation was observed.
Sunitinib in Advanced ASPS
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FISH and Western blotting analysis of PTEN. Because PTEN, the
negative regulatory effector of PI3K/AKT pathway, resulted as
wild type, we did FISH analysis of this suppressor gene, which
showed disomic pattern in three samples and low polysomy in
one. Moreover, Western blotting analysis showed that this gain
of copy number did not affect the amount of PTEN protein.
Overall, all the downstream effectors of upstream mTOR did
not show any alterations.
3. Assessment of mechanisms of activation of upstream
targets. Because the strong activation of PI3K/AKT and RAS/
ERK1/2 pathways in the absence of any upstream mTOR
effector deregulation supported an upstream RTK-driven
activation, we looked for possible mechanisms of activation.
Mutational analysis. EGFR, PDGFRA, PDGFRB, and RET were
sequenced, and no mutation was observed. We omitted MET
gene sequencing because no mutation was detected in the series
investigated by Tsuda (9).
FISH analysis. EGFR, PDGFRA, PDGFRB, MET, and RET were
analyzed by FISH, and a disomic patternwas observed in all cases.
Reverse transcription–PCR and real-time PCR analyses for
assessment of ligand expression. PDGFA, PDGFB, HGF, GDNT,
and NTN (Fig. 3D, top), as well as EGF and TGFA (Fig. 3D,
bottom), turned out to be expressed in all cases.
Taken together, the absence of mutations and gene copy
number alterations in the presence of cognate ligand expression
is consistent with an autocrine/paracrine activation loop.
Discussion
We have been treating five patients with progressive, heavily
pretreated, advanced ASPS, resistant to IFN, with continuous
SM. Among the four patients evaluable for response, two
showed a RECIST partial response, as well as a PET response.
One had a RECIST stable disease, whereas the other progressed.
Although very preliminary, these observations point to some
effectiveness of SM in ASPS. Noteworthy, dimensional
responses took place. This is of great interest in a tumor
resistant to chemotherapy (1–3). Furthermore, in one case, SM
was active for long. These findings prompted us to investigate
the upstream and downstream tyrosine kinase–related path-
ways of four patients whose frozen material from primary
tumor was available through phospho RTK antibody array,
immunoprecipitation/Western blotting, molecular analyses,
immunohistochemistry, and FISH. In all cases, the upstream
analysis showed activation of the PDGFR family, as well as
EGFR, MET families, and RET. VEGFR1/VEGFR2 were not
activated, but in one case; in particular, they were not activated
in the two patients with dimensional responses. The down-
stream target analysis showed a strong activation of PI3K/AKT,
ERK1/2, and mTOR and of its targets (S6K and S6) in the
absence of any upstream mTOR effector deregulation.
Because this pattern of activation is consistent with an RTK-
driven upstream activation, we looked for the possible
mechanisms of activation by molecular and FISH analyses.
No evidence of mutations and gain or loss of genes was found,
whereas a consistent presence of cognate ligands was promptly
detected. This is in keeping with multiple RTK-driven
autocrine/paracrine loops encompassing RTKs fitting with the
target profile of SM, in addition to EGFR and MET. These
findings give a rationale to the use of this compound, because
SM is an RTK inhibitor with direct antitumor and antiangio-
genic activity by targeting the PDGFR family, VEGFR, and RET
receptor (15–17). Moreover, an activation of all these
receptors, but KIT, was shown at upstream level; notably, a
ligand-dependent activation of PDGFRA, PDGFRB, and RET
was also observed. Remarkably, the lack of a role of KIT has
been already reported (30). Overall, our results support the
hypothesis that the antitumor activity of SM in ASPS may be
mainly mediated by PDGFRs, whereas the inhibition of
VEGFR, in keeping with available studies (8), seems to be less
relevant.
RET is an SM target. Furthermore, an alternative way to
fusion protein in inducing MET overexpression is represented
by the presence of a deregulated RAS or RET, as reported in
another tumor type (28). As in our model RAS is structurally
normal, we investigated RET and provided evidence that RET
was phosphorylated; thus, the possibility of MET overexpres-
sion induced by RET signaling could been envisioned.
Hence, our data regarding MET suggest that, in addition to
the unregulated TFE3 fusion protein expression, as shown by
preclinical assays (8, 9), the presence of an activated RET might
also concur to the activation of MET together with a potent
activation of the detected HGF ligand (28). Both mechanisms
may contribute to evoke the strong activation of PI3K/AKT and
ERK1/2 pathways. Furthermore, considering the pivotal role of
HGF/MET system in angiogenesis (31) and the peculiar
Table 2. Patient characteristics
Age (age at
the time of
diagnosis), y
Gender Performance
status
Site of primary
tumor
Site of metastasis at
the time of diagnosis
Patient A 58 (49) M 2 Right forearm None
Patient B 28 (24) M 1 Right arm Lung
Patient C 24 (24) M 3 Right leg Lung, liver, soft tissue,
bone, brain
Patient D 31 (26) M 0 Right thigh Lung
Patient E 25 (23) M 0 Right leg Lung
Patient F 55 (52) M 2 Left high Lung
Patient G 22 (20) F 1 Left thigh Lung
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vascular pattern of ASPS, our data strongly support a
therapeutic role of MET inhibitors. Currently, no data on the
activity of SM on MET are reported. However, SU5416, another
RTK inhibitor chemically related to SM with similar functional
groups, has been shown to inhibit activation of HGF/MET in
hepatocarcinoma, suggesting that SM might be involved even
in HGF/MET down-signaling switch off (32).
Regarding EGFR, owing to the constant coexpression of
PDGFRB and EGFR and the good response of the two patients
treated with SM, both carrying this coexpression, we cannot rule
out that EGFR could also be activated through a cross-talk with
activated PDGFR in PDGFR-addicted tumors (33). In fact, the
cross-activation phenomenon through intrafamily (34), as well as
interfamily, heterodimerization (28) is not unusual among RTKs.
Table 3. Results
Treatment
with
sunitinib
Duration
of
treatment
Hematologic
toxicity
Non
hematologic
toxicity
Evaluable
for
response
Symptoms
improvement
CT/MRI
response
(RECIST)
PET
response
RTK
expression
profile
Patient
A
Y 12 mo,
ongoing
Neutropenia (G2);
thrombocytopenia
(G1); anemia (G1)
Fatigue (G2),
hypothyroidism
(G2)
Y Y Partial response
after 6 wk
confirmed at
3-6-9-12 mo
Y PDGFRB,
MCSFR,
RET, MET
Patient
B
Y 10 mo,
ongoing
Neutropenia
(G1)
Nausea/vomit
(G2)
Y Y Partial response
after 6 wk
confirmed at
3 and 6 mo;
slight
progression
after 9 mo
(RECIST SD)
Y PDGFRB,
MCSFR,
FLT3, RET,
MET family
Patient
C
Y 3 mo,
stopped
None None Y N Slight
progression
after 6 wk
(RECIST SD),
progressive
disease after
3 mo
N
Patient
D
Y 4 mo,
ongoing
Neutropenia
(G1)
None Y Not
applicable
SD after 4 wk,
slight response
after 3 mo
(RECIST SD)
No
change
Patient
E
Y 1 mo,
ongoing
None None N
(too early)
Not
applicable
Too early Too
early
Patient
F
N Not applicable PDGFRB,
MCSFR,
RET, MET
Patient
G
N Not applicable PDGFRB,
MCSFR,
FLT3, RET,
MET family
Table 2. Patient characteristics (Cont’d)
Site of metastasis
before starting
sunitinib
Presence of
symptoms before
starting sunitinib
Previous surgery/
radiation therapy/
chemotherapy
Previous treatment
with IFN
Treatment with
sunitinib
Material for
biochemical
analysis
Lung, liver, soft
tissue, bone
Y Y/Y/Y Y (progression) Y Y
Lung, liver, soft
tissue, brain
Y Y/Y/Y Y (progression) Y Y
Lung, liver, soft tissue,
bone, brain
Y Y/Y/N Y (progression) Y N
Lung, liver N Y/N/Y Y (SD followed
by progression)
Y N
Lung N Y/N/Y Y (progression) Y N
Lung Y Y/Y/Y Y (SD followed
by progression)
N Y
Lung N Y/Y/N Y (SD followed
by progression)
N Y
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Finally, the strong activation of downstream signaling
supports the possibility that a combination of upstream tyrosine
kinase and downstream mTOR inhibitors could result in an
enhanced tumor growth control. This combination could also
avoid the possible rapamycin-mediated enhancement of PI3K/
AKT activation induced by silencing the S6K-mediated down-
regulation of PI3K/AKT, i.e., the so-called negative feedback loop
that might result in an attenuation of the effects of mTOR
inhibition (29).
In summary, our clinical observation, as well as biomolecular
data provided herein, may open a new opportunity for ASPS
treatment, to be prospectively evaluated in a case setting lacking
any conventional medical treatment.
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Fig. 2. Patient B. Soft tissue and lung
metastasis from right arm primaryASPS:
response to sunitinib.
Fig. 1. Patient A. Liver metastasis from
right forearm primaryASPS: response to
sunitinib.
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Fig. 3. A, spots represent the activated receptors.The double strong labeled spots at the four corners represent the positive controls. B, strong METand RET
immunodecoration was confirmed by immunoprecipitation/Western blotting experiments. Asterisks indicate the corresponding activated receptors (anti ^ p-Tyr and
anti ^ p-Ret; *) and the receptor MET(**), respectively. C, head arrows indicate p85PI3K derived from coimmunoprecipitation experiments (PDGFRB and EGFR). For each
of the other analyzed effectors, arrows indicate the activated (P) forms and the corresponding proteins. Actin is the quantitative experimental control. D, reverse
transcription ^ PCR (RT-PCR) amplification products and amplification cycles (EGF andTGFA) of the named ligands.
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